We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Medical Imaging Health IT Point of Care Business Focus

LAA Performs Pioneering Roadside Occlusive Balloon Surgery

By HospiMedica International staff writers
Posted on 30 Jun 2014
Image: Dr. Gareth Davies, medical director of the LAA (Photo courtesy of London Air Ambulance).
Image: Dr. Gareth Davies, medical director of the LAA (Photo courtesy of London Air Ambulance).
The London Air Ambulance (LAA; United Kingdom) has performed the world’s first roadside resuscitative endovascular balloon occlusion of the aorta (REBOA) to control internal bleeding.

REBOA is a proactive circulatory support method for hypotensive patients at risk of cardiovascular collapse. It works by controlling or preventing further blood loss via a balloon fed into the inferior part of the aorta and then inflated, temporarily cutting off blood supply to damaged blood vessels. Occlusion of the thoracic aorta can provide inflow control in patients with exsanguinating abdominal trauma, whereas occlusion of the infrarenal aorta can control pelvic hemorrhage.

The pioneering technique could prevent trauma patients bleeding to death from severe pelvic hemorrhage, an injury most commonly associated with cycling incidents and falls from height. The technique was developed over two year in conjunction with the Royal London Hospital (RLH; United Kingdom), the LAA’s home base, which continues treatment of the patient with further hospital interventions.

“We believe the use of REBOA can lead to a reduction in the number of patients who quite simply bleed to death before they have the chance to get to hospital where there are highly developed systems for stabilizing and preventing blood loss,” said Gareth Davies, MD, medical director of the LAA. “Our aim is to provide our patients with the world’s most innovative and effective pre-hospital care. Being able to effectively manage blood loss at the scene is a significant advancement in pre-hospital medicine.”

“We have to stop people bleeding to death—it's one of the world's biggest killers. Over 2.5 million people bleed to death from their injuries each year around the world,” added Prof. Karim Brohi, consultant vascular and trauma surgeon at RLH. “While it sounds relatively simple it is an extremely difficult technology to deliver in the emergency department in hospital, never mind at the roadside. We are excited about the potential for REBOA to reduce death and suffering after trauma and will continue to evaluate and develop the technology into the future.”

LAA is a registered charity that functions as a mobile emergency department in life-threatening, time-critical situations, and carries a senior doctor (in addition to a paramedic) at all times on a helicopter, thus reducing the death rate in severe trauma by 30%–40%. Based in RLH, the helicopter can reach any patient inside the M25 London orbital road within 15 minutes. Missions commonly involve serious road traffic collisions, falls from height, stabbings and shootings, industrial accidents, and incidents on the rail network. The team can provide advanced life-saving medical interventions, including open heart surgery, blood transfusion, and anesthesia at the scene.

Related Links:

London Air Ambulance
Royal London Hospital


Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Patient Preoperative Skin Preparation
BD ChloraPrep
Gold Member
Blood Gas Analyzer
i-Check200

Channels

Critical Care

view channel
Image: The investigational niia signature wearable patch combines continuous glucose monitoring, insulin delivery, and automated glucose control in a single system. (photo courtesy of PharmaSens)

Wearable Patch Prototype Advances Toward Integrated Automated Insulin Delivery

Diabetes management requires individualized care, reliable glucose and ketone monitoring, and timely intervention. For automated insulin delivery, a key challenge is maintaining accurate glucose measurements... Read more

Patient Care

view channel
Image Credit: Adobe Stock

AI Platform Personalizes Support Between Visits for Cancer Survivors

Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more

Medical Imaging

view channel
Image: Visual Abstract (Andrea Farolfi et al., Journal of Nuclear Medicine, 2026. DOI: 10.2967/jnumed.126.272108)

PSMA PET/CT-Guided Biopsy Improves Detection of Significant Prostate Cancer After Nondiagnostic MRI

Prostate cancer can be difficult to detect when magnetic resonance imaging (MRI) findings are negative or inconclusive. Men with persistent clinical risk factors may still require biopsy, yet standard... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: WHX returns to Dubai Exhibition Centre, Expo City, and Dubai World Trade Centre from 5–28 January 2027 (Photo courtesy of World Health Expo)

World Health Expo to Showcase Trillion-Dollar Growth Across Pharma, Biotech, Longevity and Wellness at 2027 Edition

World Health Expo (WHX) expands with the new Pharma, Biotech, Longevity and Wellness industry sectors More than 235,000 professional visits, over 4,200 exhibitors and representatives from over... Read more